Publicaciones en colaboración con investigadores/as de Sheba Medical Center (16)

2023

  1. Validation of the Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) questionnaire for adults

    Journal of Affective Disorders, Vol. 326, pp. 249-261

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  3. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)

    Journal of Affective Disorders, Vol. 299, pp. 367-376

  4. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

    Journal of Affective Disorders, Vol. 299, pp. 393-407

2021

  1. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative

    Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811

  2. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  3. Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: A report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group

    BMJ Open, Vol. 11, Núm. 11

2018

  1. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    The Lancet, Vol. 392, Núm. 10142, pp. 123-133

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Glycated hemoglobin measurement and prediction of cardiovascular disease

    JAMA - Journal of the American Medical Association, Vol. 311, Núm. 12, pp. 1225-1233

2013

  1. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

    PLoS ONE, Vol. 8, Núm. 5

  2. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 20, pp. 2586-2592

2009

  1. Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study

    Schizophrenia Research, Vol. 115, Núm. 2-3, pp. 104-114

  2. Major lipids, apolipoproteins, and risk of vascular disease

    JAMA, Vol. 302, Núm. 18, pp. 1993-2000

2008

  1. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

    The Lancet, Vol. 371, Núm. 9618, pp. 1085-1097